Dallah Healthcare Holding Company (4004) fair value: what the stock is really worth
As of Oct 28, 2026: fair value (intrinsic value) of Dallah Healthcare Holding Company stock SAR 75.04, price SAR 65.60, upside +14.4%, quality 33 out of 100. Rating: undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Oct 27, 2026.
How to read this chart
60‑month range 52.59 SAR – 150.73 SAR · fair‑value band 56.28 SAR – 93.79 SAR · the 65.60 SAR price screens below the 75.04 SAR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Oct 27, 2026.
Follow Dallah Healthcare Holding in your weekly email
Every Wednesday you see whether Dallah Healthcare Holding is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Dallah Healthcare Company operates as a health care company in the Kingdom of Saudi Arabia. The company engages in operating, managing, equipping, and developing hospitals and healthcare facilities, medical centres, complexes, and clinics; and the provision of manpower and support services.
Show moreShow less
It also offers pharmaceuticals, cosmetics, consumables, equipment, and nutritional supplements, as well as medications, diagnostics, and medical technologies.
In addition, the company provides personalized treatment plans, post-surgical recovery and chronic condition management, in-home nursing and physiotherapy, and teleconsultations and remote monitoring services.
Further, it manages private hospitals, medical and diagnostic centers, and an analytical laboratory; and provides medical services. The company was formerly known as Dallah Healthcare Holding Company and changed its name to Dallah Healthcare Company in November 2016.
The company was founded in 1987 and is based in Riyadh, Saudi Arabia.
Stock analysis
Dallah Healthcare Holding Company (4004) currently trades at 65.60 SAR, while our model-based Fair Value estimate is 75.04 SAR, implying the stock looks roughly 12.6% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 112.56 SAR per share, and 7 of the 16 models we run sit above the 65.60 SAR price.
Bear case: the Economic Profit group reads lowest at 12.61 SAR, and 9 of the 16 models stay below the price. Data coverage for this calculation is high.
Scenario range: 56.28 SAR (bear) to 93.79 SAR (bull), the price of 65.60 SAR sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 33/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Dallah Healthcare Holding Company reported revenue of 4.1B SAR in FY2025 versus 2.1B SAR in FY2021, a compound +17.9%/yr. Reported net income was 538M SAR in FY2025, compounding +20.1%/yr from FY2021.
Key figures
Market cap 7.3B SAR (≈ $2.0B) Small · P/E ratio 18.2 · P/S ratio 1.71 · EPS (TTM) 3.61 SAR · Dividend yield 2.5% · Net margin 10.3% · Return on equity 10.3% · Return on assets (EBIT) 7.8%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 51 out of 100 (low confidence).
What moves the price
The share trades about 48% below its 52-week high and 9% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 19% fair-value upside, at 14%, 4004 screens richer than that median.
Fair Value models
Bear56.28 SARFair Value 75.04 SARBull93.79 SAR
Price 65.60 SAR · Upside +14.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (1.61 SAR per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+26.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+25.3%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+21.7%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis.
+28.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year+25.5%
Dividend (yield on the price)2.5%
Per share before 2019divided by the spin-off factor 1.2712
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.25.8% vs 13.9%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.10% → 14%
Compare Dallah Healthcare Holding Company with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 243 stocks
Beats the industry median on 8/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score33 · Bottom 25%
Fair Value upside+14.4% · Above median
Profitability
Return on equity (12 months)10.3% · Above median
Return on assets5.9% · Above median
Net margin (12 months)10.3% · Above median
Operating margin (12 months)13.5% · Above median
Growth and dividend
Revenue growth (quarter YoY)4.3% · Below median
Dividend yield (12 months)2.5% · Above median
Balance sheet
Debt / equity0.72× · Highest 25%
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Dallah Healthcare Holding Company Fair Value". https://www.fairvalue-calculator.com/stock/4004
Frequently asked questions
Is Dallah Healthcare Holding Company (4004) overvalued or undervalued?
As of Oct 27, 2026, our model estimates a fair value of 75.04 SAR versus a price of 65.60 SAR, about +14% upside (undervalued).
What is the fair value of 4004?
Our model-based fair value for Dallah Healthcare Holding Company is 75.04 SAR (as of Oct 27, 2026), built from audited fundamentals. The current price: 65.60 SAR.
What is the quality score of 4004?
Dallah Healthcare Holding Company has a Quality Score of 33/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Dallah Healthcare Holding Company (4004)?
Our model-based price target is the fair value of 75.04 SAR (as of Oct 27, 2026) from 16 valuation models. Cautious scenario 56.28 SAR, optimistic scenario 93.79 SAR. It is a calculation from audited fundamentals, not an analyst target.
What is the Dallah Healthcare Holding Company stock forecast for 2026?
Our models put fair value at 75.04 SAR, about +14% upside versus a price of 65.60 SAR (undervalued). Cautious scenario 56.28 SAR, optimistic scenario 93.79 SAR. The calculation is refreshed regularly with new filings.
What is the revenue of Dallah Healthcare Holding Company (4004)?
Dallah Healthcare Holding Company reported trailing-twelve-month revenue of about 4.3B SAR (latest available figure, as of Oct 27, 2026).
Does Dallah Healthcare Holding Company pay a dividend?
Dallah Healthcare Holding Company currently shows a dividend yield of 2.54% relative to its recent price (as of Oct 27, 2026).
What is the intrinsic value of Dallah Healthcare Holding Company (4004)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Dallah Healthcare Holding Company it is 75.04 SAR per share (as of Oct 27, 2026), against a price of 65.60 SAR. It is the blended result of 16 valuation models (cash flow, earnings, asset, dividend).
Is Dallah Healthcare Holding Company stock overvalued or undervalued in 2026?
As of Oct 27, 2026, 4004 trades below its calculated fair value: price 65.60 SAR, fair value 75.04 SAR, a gap of about +14% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 4004?
No. The price is what the market pays today (65.60 SAR); the fair value is what the company's own numbers justify (75.04 SAR). For Dallah Healthcare Holding Company the two are 9.44 SAR per share apart. That gap is exactly why we show both numbers side by side.
How much is Dallah Healthcare Holding Company worth?
The market values Dallah Healthcare Holding Company at about 7.3B SAR (market capitalisation, as of Oct 27, 2026). Per share that is 65.60 SAR; our models calculate a fair value of 75.04 SAR per share.
What do the bullish and bearish scenarios say about 4004?
Our models span a range for Dallah Healthcare Holding Company: cautious scenario 56.28 SAR, base 75.04 SAR, optimistic 93.79 SAR per share (as of Oct 27, 2026, price 65.60 SAR). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 4004?
Dallah Healthcare Holding Company trades at a price-to-earnings ratio of 18.2 (as of Oct 27, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 75.04 SAR is built from several models across several years. Excluding one-off items of fiscal year 2025 it is 14.8 (reported for FY2025: 12.4). Other multiples: P/B 1.8, P/S 1.7, EV/EBITDA 14.0.
How solid is the balance sheet of Dallah Healthcare Holding Company (4004)?
Balance-sheet figures for Dallah Healthcare Holding Company (as of Oct 27, 2026): return on equity 10.3%, debt of 0.72 per unit of equity. They feed the Quality Score of 33/100, which measures business quality independently of the share price.
How far is 4004 from its 52-week high?
Dallah Healthcare Holding Company trades at 65.60 SAR, about 48% below its 52-week high of 126.16 SAR and 9% above the low of 60.00 SAR (as of Oct 28, 2026). Distance from the high says nothing about value: that is what the fair value of 75.04 SAR is for.
Which stocks are comparable to Dallah Healthcare Holding Company?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Dr. Sulaiman Al Habib Medical Services Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Dallah Healthcare Holding Company stock attractive at the current price?
The data as of Oct 27, 2026: price 65.60 SAR, calculated fair value 75.04 SAR (+14%), Quality Score 33/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 4004 calculated?
We run Dallah Healthcare Holding Company through 16 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 75.04 SAR, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.4 % above its aggregate fair value. Dallah Healthcare Holding Company currently trades 13 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Dallah Healthcare Holding Company (4004)?
The closing price on Oct 28, 2026 was 65.60 SAR. Our model-based fair value is 75.04 SAR, about +14% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Dallah Healthcare Holding Company right now?
The price sits in the lower half of our model range, the side with the larger margin of safety. The data supports the verdict: every model runs on fully documented inputs.
Where does the earnings growth of Dallah Healthcare Holding Company (4004) come from?
Earnings per share at Dallah Healthcare Holding Company grew +9.8 % a year from 2014 to 2025. Broken into its drivers: revenue per share +13.2 %, EBIT margin −1.3 %, tax rate +0.3 %, residual (interest, one-offs) −2.1 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Dallah Healthcare Holding Company
How large is the market capitalisation of Dallah Healthcare Holding Company (4004)?
The market capitalisation of Dallah Healthcare Holding Company is 7.3B SAR (≈ $2.0B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Dallah Healthcare Holding Company (4004)?
The price-to-sales ratio of Dallah Healthcare Holding Company is 1.71 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Dallah Healthcare Holding Company (4004)?
Earnings per share at Dallah Healthcare Holding Company are 3.61 SAR (price ÷ EPS = P/E 18.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Dallah Healthcare Holding Company (4004)?
The dividend yield of Dallah Healthcare Holding Company is 2.5% (payout 55.1%, on adjusted earnings, reported 46.2%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Dallah Healthcare Holding Company (4004)?
The net margin of Dallah Healthcare Holding Company is 10.3% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Dallah Healthcare Holding Company (4004)?
The return on equity (ROE) of Dallah Healthcare Holding Company is 10.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Dallah Healthcare Holding Company (4004)?
On an EBIT basis the return on assets of Dallah Healthcare Holding Company is 7.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Dallah Healthcare Holding Company (4004)?
The operating margin of Dallah Healthcare Holding Company is 13.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Dallah Healthcare Holding Company (4004)?
Revenue at Dallah Healthcare Holding Company is growing +4.3% versus a year earlier (3y avg +17.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Dallah Healthcare Holding Company (4004)?
Earnings per share at Dallah Healthcare Holding Company are growing −19.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Dallah Healthcare Holding Company (4004) generate?
The free cash flow of Dallah Healthcare Holding Company is −79.4M SAR (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Dallah Healthcare Holding Company (4004) carry?
The net debt of Dallah Healthcare Holding Company is 3.7B SAR (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Dallah Healthcare Holding Company in the live analysis
One click puts Dallah Healthcare Holding Company on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Broad data
Oct 27, 2026